Caris Assure: Advancing Clinical & Biopharma Insight Through Liquid Biopsy
- Expanding WES-based reporting to incorporate pharmacogenomic and emerging biomarkers (e.g., DPYD)
- CHIP-aware liquid biopsy interpretation to reduce false positives and strengthen variant confidence
- Real-world case studies